Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

or 510.856.5598.

 ANTHERA PHARMACEUTICALS, INC.(A Development Stage Company)CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share data)(unaudited)Three Months Ended March 31,20132012Operating expenses:Research and development

$

4,929

(1)$

17,738General and administrative1,972

(2)2,322Total operating expenses6,90120,060Loss from operations(6,901)(20,060)Other income (expenses):Other income (expense) - net25(10)Interest expense(704)(843)Total other (expense) - net(679)(853)Net loss attributable to common stockholders

$

(7,580)$

(20,913)Net loss per share attributable to common stockholders:Basic and diluted

 

$

 

(0.06) 

$

 

(0.51)Weighted-average number of shares used to compute net loss per share of common stock—basic and diluted 

124,124,066 

41,000,421(1)

Included in research and development expenses is a one-time charge of stock-based compensation of approximately $799,000 associated with the voluntary surrender of stock options by our employees during the three months ended March 31, 2013.(2)

Included in general and administrative expenses is a one-time charge of stock-based compensation of approximately $661,000 associated with the voluntary surrender of stock options by our employees during the three months ended March 31, 2013. 

 ANTHERA PHARMACEUTICALS, INC.(A Development Stage Company)BALANCE SHEET DATA(in thousands, except share data)(unaudited)March 31, 2013December 31,
2012Cash and cash equivalents

$
50,570$
9,431Short term investments

$
3,824$
5,322Total assets

$
56,452$
26,445Total current liabilities, excluding current portion of notes payable

$
4,706$
9,421Total notes payable

$
8,393$
20,550Deficit accumulated during development
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Drug delivery technologies that improve access and ... the entire drug development process. Pharmaceutical companies are ... delivery technologies in a bid to move away ... New analysis from Frost & Sullivan, ... delivery sector currently makes up a small fraction ...
(Date:9/2/2014)... , Sept. 2, 2014 Legal-Bay LLC, ... increase in capital and cash advance funding for ... System,s da Vinci Robot. With over 400k surgeries ... focuses on providing lawsuit cash advances for victims ... damage, lacerations to internal organs, burns to blood ...
(Date:9/2/2014)... 2, 2014 /PRNewswire-iReach/ -- WCCT Global, a multi-site ... of the fastest growing companies in America by ... company has undergone significant growth in four main ... clinical development, anti-viral and vaccine development, and patient ... has successfully participated in over 150 early and ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3da Vinci Lawsuit Settlement Funding Amounts Increased at Legal-Bay Funding 2da Vinci Lawsuit Settlement Funding Amounts Increased at Legal-Bay Funding 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2
... Pharmaceutical International Co., Ltd. (the "Company") (OTC Bulletin Board: ... obtained the exclusive sales rights of Thymosin Alpha 1 ... Pharmaceutical Co. I. The State Food and ... permit of Thymosin Alpha 1 Injection for Shanghai Biochemistry ...
... Health IT Services Group announced today that Acumen ... as a Complete EHR on December 30, 2010, by ... ONC-ATCB, in accordance with the applicable Eligible Provider certification ... Services. The 2011/2012 criteria support the Stage 1 meaningful ...
Cached Medicine Technology:Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection 2Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection 3Health IT Services Group's Acumen EHR, Version 6.0, Receives ONC-ATCB 2011/2012 Certification 2Health IT Services Group's Acumen EHR, Version 6.0, Receives ONC-ATCB 2011/2012 Certification 3
(Date:9/2/2014)... 2 September 2014: Health structures explain nearly 20% ... to the results of a joint ESC-OECD study ... Maggioni. Clinical variables explained more than 80% of ... unique evaluation which combines clinical data and health ... fuller picture of the reasons some patients with ...
(Date:9/2/2014)... Developers and plugin specialist of Final Cut ... from Pixel Film Studios. , “ProIntro has enabled users ... Christina Austin, CEO of Pixel Film Studios. “Blurring the ... game changer.” , Learn how to create a title ... Studios. ProIntro is a package of professionally designed titles ...
(Date:9/2/2014)... NOVAtime Technology, Inc. ( http://www.novatime.com ... announced today that Avon Health Center, a long-time ... NOVAtime 4000 Time and Attendance / Workforce ... latest smart clock, the NT7000 . , Avon ... is an award-winning nursing facility that provides short-term ...
(Date:9/2/2014)... “Harmonicas have been formally used ... to help people with COPD or asthma. At ... systems,” says Dana Keller, PhD, co-inventor of the ... are much the same – improved health with ... harmonica.” , The three approaches to harmonicas in ...
(Date:9/2/2014)... September 02, 2014 September 2014 – The ... gone. But even though men shave daily – and commit ... rough and irritated skin isn’t inevitable, according to Joshua ... , For decades, skin care was something in which ... surge in men of all ages who realize that their ...
Breaking Medicine News(10 mins):Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 3
... dengue fever in early stage was launched in India Monday ... distributor of life science research products and clinical diagnostics. ... to diagnose dengue on the first day of symptoms, the ... - the first in the Indian market - is based ...
... to be safer to use than laser surgery to correct ... being contested by a physician William Mathers, M.D from Health ... comparing data from many recent studies who feels the results ... ,Dr Mathers, Professor of Ophthalmology in the OHSU School ...
... have quit the NHS rather than sign new contracts. Around ... around one million patients without an NHS dentist. ... over the changes. If their issues are still not resolved, ... switch to private practice. ,Since the introduction of ...
... term schizophrenia should be done away with, as it has ... is a harmful concept," said Professor Marius Romme, a visiting ... in Birmingham.,He added, "Symptoms such as delusions, hearing voices and ... be reactions to traumatic and troubling events in life. " ...
... medicine regulators to begin selling its new breast cancer pill ... last month, and comes slightly earlier than some commentators were ... GSK's most promising pipeline drugs as well as a potential ... the drug could cross 2 bln used by 2010. ...
... patients before the surgical removal of the tumour, than ... 1 %. The usual treatment for bowel cancer ... and once reappeared, treatment is difficult and usually incurable. ... to compare the effect of radiotherapy before and after ...
Cached Medicine News:Health News:Laser Surgery Safer Than Contact Lenses? 2Health News:NHS Dentists Shortage worsens over New Contracts 2Health News:‘Schizophrenia’ term ought to be abolish 2
Mid-level interpretive resting ECG...
... The ECG-9010 meets IEC60601-2-51 new ... accuracy and digital filter performance. ECG ... on a Windows PC with the ... be changed for operating in other ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... Critical Care Xpress is an innovative, stat ... and hematology with on-board co-oximetry and integrated ... instrument. Measured tests include pH, PCO 2 ... hematocrit and hemoglobin, sodium, potassium, chloride, ionized ...
Medicine Products: